| Molecule | Cat. No. | Product Name | Espèce | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| CEACAM-8 | Human CEACAM-8 / CD66b Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $390.00 100ug | |||
| CEACAM-8 | Avitag CE8-H82E9 | Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™ (SPR verified) | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| 90Y-DTPA-besilesomab | TLX-66 | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Besilesomab | 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183 | Approved | Cis Bio International Sa | Scintimun | EU | Osteomyelitis | Cis Bio International Sa | 2010-01-11 | Osteomyelitis | Details |